September 16, 2026 · News

China Medtech Disclosures: Tinavi Restructures and Secures Software NMPA, Broncus Expands BroncAblate Reach

Late August and early September 2026 regulatory filings and interim reports from Chinese surgical device developers reveal significant shifts in organizational size, product portfolio development, and capital operations across the domestic ecosystem. Tinavi disclosed a sharp reduction in total staffing alongside the receipt of a key regulatory approval for its orthopedic planning software, while advancing a major equity acquisition in the orthopedic sector. Simultaneously, Broncus Medical outlined the clinical reach of its core ablation platform and detailed its mid-year personnel allocation across domestic and international locations.

Tinavi: Class III Software Clearance and Workforce Adjustments

On August 7, 2026, Tinavi received a Class III medical device registration certificate from China’s National Medical Products Administration (NMPA) for its proprietary orthopedic surgical planning software, filed under certificate number 国械注准20263211672. The approved software product is designed to be used in conjunction with the company’s orthopedic surgical navigation and positioning system. This regulatory clearance formalizes the software element that operates alongside the hardware positioning platforms previously developed by the company.

Nineteen days after obtaining this certificate, Tinavi issued disclosure documents on August 26, 2026, detailing the size and composition of its operational workforce as of the close of the first half of the year. As of June 30, 2026, the company reported a total of 323 in-service employees. Among these 323 personnel, 109 individuals were assigned to research and development functions.

This represents an organizational reconfiguration when measured against earlier reporting periods, where the site previously listed employee headcount at more than 500 personnel. Based on the newly published figures, research and development personnel constitute approximately one-third of the company’s 323-person workforce. The reduction to 323 total employees demonstrates an adjustment in organizational scale while maintaining an in-house technical team of 109 R&D staff to advance combined software and hardware platforms.

Major Asset Restructuring: Planned Acquisition of Shanghai MicroPort Orthopedics

Following its interim personnel disclosure, Tinavi provided an update on August 29, 2026, regarding a major asset restructuring process. The company disclosed that it intends to acquire a 62% equity interest in Shanghai MicroPort Orthopedics Medical Technology Co., Ltd.

According to the announcement, the transaction is structured through the issuance of shares to purchase the target asset. In parallel with the equity purchase, Tinavi plans to raise supporting funds as part of the asset restructuring package.

The proposed transaction focuses specifically on consolidating a 62% controlling interest in Shanghai MicroPort Orthopedics Medical Technology, signaling an asset-level expansion into broader orthopedic medical technologies alongside Tinavi’s core positioning systems and newly certified planning software. The use of share issuance to fund the 62% stake acquisition preserves direct cash balances while integrating the target’s corporate structure into Tinavi’s balance sheet.

Broncus Medical: Interim Headcount and BroncAblate Deployment

Broncus Medical published its interim results announcement on August 27, 2026, setting out organizational figures as of June 30, 2026. As of that reporting date, the group employed 195 individuals in total. Geographically, the workforce is heavily concentrated within the domestic market, with 174 employees based in China. The remaining 21 employees are stationed internationally, located primarily across the United States, Europe, and India. Based on these disclosures, domestic personnel account for approximately 90% of the group’s total workforce, underscoring that operational resources remain centered primarily in China.

On the same date, Broncus disclosed operational progress for its core product, the BroncAblate lung radiofrequency ablation system. As of June 30, 2026, the BroncAblate platform had established coverage across roughly 30 provinces and municipalities in China. Within these territories, the system has entered nearly 40 hospitals.

In terms of procedural adoption, the system had accumulated more than 300 clinical applications post-market by the end of June 2026. These figures highlight the initial commercial distribution network for BroncAblate, demonstrating that clinical utilization has expanded beyond local trial centers into a multi-provincial installation base across close to 40 medical institutions.

MicroPort MedBot: Trading Suspension on the Hong Kong Stock Exchange

On September 1, 2026, MicroPort MedBot announced that trading in its H shares on the Stock Exchange of Hong Kong (stock code: 02252.HK) was suspended effective from 9:00 AM. All structured products related to the company were suspended from trading simultaneously with the equity securities.

Patterns & Outlook

The disclosures filed between August 7 and September 1, 2026, provide distinct reference points regarding how Chinese surgical and interventional technology developers manage operational capacity, regulatory assets, and compliance requirements.

First, the comparative staffing data between Tinavi and Broncus reveals varying workforce structures among publicly listed medtech firms in China. Tinavi closed June 2026 with 323 employees, down from a previously recorded level of over 500, but maintained a focused cadre of 109 research and development staff. In contrast, Broncus reported an overall group headcount of 195 individuals, maintaining a leaner total organization that relies predominantly on domestic staff (174 employees) supported by an overseas presence of 21 personnel in key regions including the US, Europe, and India.

Second, corporate growth strategies reflect a balance between software-driven internal development and inorganic consolidation. Tinavi secured a domestic Class III registration for planning software explicitly paired with its surgical navigation and positioning hardware. Concurrently, it initiated a major capital restructuring to purchase a 62% stake in Shanghai MicroPort Orthopedics Medical Technology via share issuance. This dual approach pairs indigenous regulatory clearances with corporate equity expansion to build scale in orthopedics.

Finally, commercial and administrative metrics provide tangible indicators of market integration and capital market status. Broncus substantiated the market progress of its BroncAblate platform with verified data: adoption across approximately 30 provincial regions, presence in nearly 40 hospitals, and a procedural volume exceeding 300 post-market clinical cases.

Last modified: September 16, 2026